Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Stem cell-based risk scoring tool could predict AML patient’s response to standard treatment

Leukemia researchers at Princess Margaret Cancer Centre have developed a 17-gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard treatment.

8 Dec 2016

New research reveals role of two genetic mutations in subset of acute myeloid leukemia

Two genetic mutations known to play a role in many solid cancers might also help explain why a subset of acute myeloid leukemia (AML) patients develop the disease, according to new research from The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

7 Dec 2016

Experimental T-cell therapy shows promise in preventing AML relapse

Fred Hutchinson Cancer Research Center announced promising results from an early trial in which patients with high-risk acute myeloid leukemia received genetically engineered immune cells.

6 Dec 2016

Simple, coordinated approach can improve chances of survival for high-risk AML patients

New research shows that quickly identifying patients with high-risk acute myeloid leukemia (AML), and speeding the process to find them a stem cell donor and performing the transplant earlier, can significantly improve their chances of surviving for at least two years after diagnosis without a relapse.

5 Dec 2016

New study finds smoking cessation at any age reduces risk of death

Tobacco use continues to be a major cause of cancer and premature death. Most studies of cigarette smoking and mortality have focused on middle-aged populations, with fewer studies examining the impact of tobacco cessation on disease and mortality risk among the elderly.

30 Nov 2016

Cancer gene mutations can predict response to less intensive treatment in AML patients

Patients with the most lethal form of acute myeloid leukemia (AML) - based on genetic profiles of their cancers - typically survive for only four to six months after diagnosis, even with aggressive chemotherapy.

23 Nov 2016

Implementation of large-scale genomic tumor profiling viable but faces several challenges

Researchers leading the largest genomic tumor profiling effort of its kind say such studies are technically feasible in a broad population of adult and pediatric patients with many different types of cancer, and that some patients can benefit by receiving precision drugs targeted to their tumors' mutations or being enrolled in clinical trials.

18 Nov 2016

ASH partners with other organizations to address knowledge gaps in AML care

The American Society of Hematology has partnered with several organizations on independent educational programming designed to help address knowledge gaps in the diagnosis and treatment of acute myeloid leukemia (AML).

8 Nov 2016

Scientists discover novel therapeutic target and treatment strategy for acute myeloid leukemia

University of Hawai'i Cancer Center researchers discovered a novel therapeutic target and treatment strategy for acute myeloid leukemia, a cancer of the blood and bone marrow that normally requires prompt and aggressive treatment.

2 Nov 2016

Fred Hutchinson opens first-of-its-kind clinic to provide new immunotherapies for cancer patients

Fred Hutchinson Cancer Research Center today announced the official opening of a first-of-its-kind clinic dedicated to providing innovative immunotherapies for cancer patients in clinical trials.

2 Nov 2016

Nano-biointeraction and nanopathology

Nanoparticles enter the organism in a number of ways. In most cases through inhalation and ingestion. When inhaled, the majority of them are expelled with the next breath. When ingested, most of them are gotten rid of through feces.

31 Oct 2016

Blocking critical molecule with therapeutic antibody could effectively reduce leukemia burden

Acute myeloid leukemia (AML) is an aggressive cancer known for drug resistance and relapse. In an effort to uncover new treatment strategies, researchers at University of California San Diego School of Medicine and Moores Cancer Center discovered that a cell surface molecule known as CD98 promotes AML.

27 Oct 2016

Novel lipid-based therapeutic shows promise for combating drug resistance in AML

Researchers at the Medical University of South Carolina Hollings Cancer Center have discovered a mechanism that confers resistance to drugs used to treat certain types of acute myeloid leukemia (AML).

24 Oct 2016

New oncogene may contribute to high incidence of prostate cancer among African American men

A team of scientists has identified MNX1 as a new oncogene - a gene than can cause cancer - that is more active in African American prostate cancer than in European American prostate cancer.

21 Oct 2016

Cleveland Clinic cancer researchers receive $2.4 million grant from NIH NHLBI

The National Institutes of Health National Heart, Lung and Blood Institute has awarded a $2.4 million grant over four years to Cleveland Clinic cancer researchers Jaroslaw Maciejewski, M.D., and Richard Padgett, Ph.D., to test the hypothesis that alterations in the pattern of splicing of target genes play a major role in the establishment or progression of myelodysplastic syndromes (MDS).

14 Oct 2016

Researchers awarded grant to develop safer cancer therapies for children

Two Case Western Reserve University School of Medicine researchers are receiving new funding from California-based St. Baldrick's Foundation for promising childhood cancer research.

5 Oct 2016

High out-of-pocket costs may delay Medicare patients' access to novel targeted treatment for cancer

Significant out-of-pocket costs that cancer patients can face before Medicare insurance drug benefits kick in may delay the patients' treatment with a novel class of targeted therapies, according to a University of North Carolina Lineberger Comprehensive Cancer Center-led study.

4 Oct 2016

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

The Alzheimer's Drug Discovery Foundation announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna for use as a cancer therapy) in patients with Alzheimer's disease.

29 Sep 2016

Antibody drug offers new therapeutic approach for treating AML

An antibody drug that targets a surface marker on cancer stem cells could offer a promising new therapeutic approach for treating acute myeloid leukemia (AML), a form of blood cancer that affects an estimated 50,000 people in Saudi Arabia.

24 Sep 2016

Novel immunotherapy shows promise against AML in clinical trial

A new type of immunotherapy shows promise against cases of acute myeloid leukemia (AML) that recur after treatment or that never respond to therapy in the first place.

21 Sep 2016